Q-omics provides the consensus-scored TSPYL1 profile across patient tissues and cancer cell-line models. TSPYL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSPYL1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TSPYL1 RNA expression shows 20,101 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where TSPYL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPYL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPYL1 survival associations across molecular data types. TSPYL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPYL1 RNA expression–survival associations across cancer types. High TSPYL1 expression shows unfavorable associations in HNSC and DLBC, but favorable associations in KIRC, MESO, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSPYL1 RNA expression.
This table summarizes TSPYL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPYL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPYL1 shows lower tumor expression in BLCA, KICH, KIRC, COAD, LUAD and KIRP. The BLCA box plot shows higher TSPYL1 RNA expression in normal versus tumor tissue (log2 FC = −0.686, t-test p < 0.001).
This table shows molecular features associated with TSPYL1 in patient tissues and cancer cell lines. In patient samples, TSPYL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPYL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
